The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| GBLX | -93.88% | -99.61% | -66.9% | -100% |
| S&P | +13.95% | +78.35% | +12.25% | +273% |
GB Sciences, Inc. is a phytomedical research and biopharmaceutical drug development company, which engages in the research and development of plant-based medicines and plans to produce plant-inspired and complex therapeutic mixtures based on its portfolio of intellectual property. The company was founded on April 4, 2001 and is headquartered in Las Vegas, NV.
No news articles found for Gb Sciences.
| Q4 2024 | YOY Change | |
|---|---|---|
| Revenue | $97.24K | 0.0% |
| Gross Profit | $0.00K | 0.0% |
| Market Cap | $1.63M | 0.0% |
| Market Cap / Employee | $814.15K | 0.0% |
| Employees | 2 | 0.0% |
| Net Income | -$100.36K | 0.0% |
| EBITDA | -$66.59K | 0.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2024 | YOY Change | |
|---|---|---|
| Net Cash | $3.02K | 0.0% |
| Inventory | 0 | 0.0% |
| Q4 2024 | YOY Change | |
|---|---|---|
| Long Term Debt | $557.00K | 0.0% |
| Short Term Debt | $1.44M | 0.0% |
| Q4 2024 | YOY Change | |
|---|---|---|
| Return On Assets | -863.43% | 0.0% |
| Return On Invested Capital | 989.20% | 0.0% |
| Q4 2024 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$124.30K | 0.0% |
| Operating Free Cash Flow | -$124.30K | 0.0% |
| Metric | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | -0.56 | -0.62 | -0.42 | -0.28 | - |
| Price to Sales | 16.75 | - | |||
| Price to Tangible Book Value | -0.56 | -0.62 | -0.42 | -0.28 | - |
| Enterprise Value to EBITDA | -12.08 | -19.96 | -26.02 | -54.36 | - |
| Total Debt | $1.76M | $1.76M | $1.87M | $1.99M | - |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
